NMD PHARMA NEUROMUSCULAR DISORDERS
LIVE

Serial Number

79432114

Owner

NMD Pharma A/S

Attorney

Julie A. Greenberg

Filing Date

Jul 15, 2025

Add to watchlist:

No watchlists yet
View on USPTO

NMD PHARMA NEUROMUSCULAR DISORDERS Trademark

Serial Number: 79432114

NMD PHARMA NEUROMUSCULAR DISORDERS is a trademark filed by NMD Pharma A/S on July 15, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

NMD Pharma A/S (4 trademarks)

Palle Juul-Jensens Boulevard 82

Entity Type: 98

Trademark Details

Filing Date

July 15, 2025

Registration Date

Not Registered

Published for Opposition

August 4, 2026

Goods & Services

Chemical-pharmaceutical preparations for the treatment of rare and genetic diseases; chemical-pharmaceutical preparations for the treatment of neurodegenerative diseases; chemical-pharmaceutical preparations for the treatment of neuromuscular disorders; chemical-pharmaceutical preparations that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; chemical-pharmaceutical preparations for the treatment of neuromuscular disorders caused by compromised skeletal muscle excitability; diagnostic preparations for medical purposes; reagents for medical purposes and for research; preparations for analysis for medical and research purposes; pharmaceutical and medical preparations for the treatment of rare and genetic diseases; pharmaceutical and medical preparations for the treatment of neurodegenerative diseases; pharmaceutical and medical preparations for the treatment of neuromuscular disorders; pharmaceutical and medical preparations that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; pharmaceutical and medical preparations for acute hospital care, namely, chemical-pharmaceutical preparations for the reversal of neuromuscular blockade, chemical-pharmaceutical preparations for the treatment of intensive care unit acquired muscle weakness, chemical-pharmaceutical preparations for the treatment of neuromuscular disorders caused by infections

Scientific and technological services and research, namely, research in the field of medicine and the development of pharmaceutical preparations; industrial analysis and research services in the field of development of pharmaceutical preparations, and in the field of identification of drug candidates; drug discovery services; basic research and clinical research, hereunder in the field of medicine and vaccine development; development of medical treatments related to rare and genetic diseases; development of medical treatments related to neurodegenerative diseases; development of medical treatments related to neuromuscular disorders; development of medical treatments that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; development of medical treatments for acute hospital care

Filing History

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 4, 2026 NPUB
PUBLISHED FOR OPPOSITION
Aug 4, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 29, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 6, 2026 CNSA
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 6, 2026 GNEN
EXAMINER'S AMENDMENT ENTERED
Jul 6, 2026 XAEC
EXAMINERS AMENDMENT E-MAILED
Jul 6, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 6, 2026 CNEA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 6, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 6, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 6, 2026 REAP
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 12, 2026 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 12, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 12, 2026 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 12, 2026 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 12, 2026 COAR
REFUSAL PROCESSED BY IB
Feb 12, 2026 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 19, 2026 RFCS
REFUSAL PROCESSED BY MPU
Jan 18, 2026 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 4, 2025 RFCR
NON-FINAL ACTION WRITTEN
Dec 3, 2025 CNRT
ASSIGNED TO EXAMINER
Dec 3, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 10, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 10, 2025 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Nov 8, 2025 LIMI
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Sep 4, 2025 SDRC